Singapore, Dec. 15 -- Japan-basedOlympus Corporationhas announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II. Building on the success of the initial fund, Olympus will deploy $150 million to invest in promising MedTech startup companies focused on Gastrointestinal (GI), Urology and Respiratory.

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A opportunities, partnerships, and valuable market insights. OIV is stage-agnostic, prioritising early to growth-stage companies globally with therapeutic solutions for targeted medical specialties.

In addition to capital, ...